Advanced Solid Tumors
Advanced Solid Tumors are a type of cancer that forms solid masses in various organs and tissues, often indicating that the disease has progressed and may require more intensive treatment options.
Advanced Solid Tumors: Repotrectinib Study
We are testing a new treatment called repotrectinib for patients with advanced solid tumors that have specific genetic changes. The study aims to evaluate its safety and effectiveness in improving tumor response.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 75 years old?
- Do you have a solid tumor that has spread (metastatic) or is locally advanced (Stage III)?
- Have you been diagnosed with a ROS1 or NTRK gene fusion?
- Are you currently taking any strong medications that affect liver enzymes, like Ketoconazole or Rifampin?
- Have you had major surgery or radiation therapy in the last 4 weeks?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
UZ Leuven
Pneumology
Heverlee, Belgium
Copenhagen University Hospital
Department of Oncology
Copenhagen, Denmark
Centre Hospitalier Universitaire Grenoble Alpes
Oncology
La Tronche, France
Sponsor: Turning Point Therapeutics Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.